Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this insightful session on understanding the evolving landscape of first-line treatment for Urothelial Carcinoma. Frontline management of urothelial carcinoma is undergoing a significant transformation, driven by groundbreaking research and the introduction of novel therapeutic agents. Traditionally, platinum-based chemotherapy has been the cornerstone, but recent advancements, particularly in immunotherapy and antibody-drug conjugates, are redefining the standard of care. This shift offers patients more effective and often better-tolerated options, moving towards a more personalized approach to treatment.
The integration of advanced molecular profiling is increasingly crucial, enabling healthcare providers to identify specific biomarkers and tailor treatment strategies for individual patients. This personalized approach not only maximizes therapeutic efficacy but also aims to mitigate adverse effects. Expert insights from specialists like Dr. Petros Grivas are vital in navigating these complex treatment decisions, ensuring that patients with urothelial carcinoma receive optimal care from the outset.
Therefore, gain an overall knowledge on the dynamic landscape of first-line treatment for urothelial carcinoma. Listen to this webinar, grab the shared knowledge from Dr. Petros Grivas, and follow Hidoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.
2.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
3.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
4.
According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.
5.
A garden can save your life
1.
Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy
2.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
3.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
4.
Cracking the Code of Subdural Hematomas: Modern Strategies for Optimal Care
5.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
4.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation